Top

Published in:

Open Access 01-09-2020 | Osteoporosis | Review

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

Authors: D. Cornelissen, S. de Kunder, L. Si, J.-Y. Reginster, S. Evers, A. Boonen, M. Hiligsmann, On behalf of the European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

Published in: Osteoporosis International | Issue 9/2020

Abstract

Summary

An earlier systematic review on interventions to improve adherence and persistence was updated. Fifteen studies investigating the effectiveness of patient education, drug regimen, monitoring and supervision, and interdisciplinary collaboration as a single or multi-component intervention were appraised. Multicomponent interventions with active patient involvement were more effective.

Introduction

This study was conducted to update a systematic literature review on interventions to improve adherence to anti-osteoporosis medications.

Methods

A systematic literature review was carried out in Medline (using PubMed), Embase (using Ovid), Cochrane Library, Current Controlled Trials, ClinicalTrials.gov, NHS Centre for Review and Dissemination, CINHAL, and PsycINFO to search for original studies that assessed interventions to improve adherence (comprising initiation, implementation, and discontinuation) and persistence to anti-osteoporosis medications among patients with osteoporosis, published between July 2012 and December 2018. Quality of included studies was assessed.

Results

Of 585 studies initially identified, 15 studies fulfilled the inclusion criteria of which 12 were randomized controlled trials. Interventions were classified as (1) patient education (n = 9), (2) drug regimen (n = 3), (3) monitoring and supervision (n = 2), and (4) interdisciplinary collaboration (n = 1). In most subtypes of interventions, mixed results on adherence (and persistence) were found. Multicomponent interventions based on patient education and counseling were the most effective interventions when aiming to increase adherence and/or persistence to osteoporosis medications.

Conclusion

This updated review suggests that patient education, monitoring and supervision, change in drug regimen, and interdisciplinary collaboration have mixed results on medication adherence and persistence, with more positive effects for multicomponent interventions with active patient involvement. Compared with the previous review, a shift towards more patient involvement, counseling and shared decision-making, was seen, suggesting that individualized solutions, based on collaboration between the patient and the healthcare provider, are needed to improve adherence and persistence to osteoporosis medications.

Available only for authorised users

Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8. https://doi.org/10.1007/s11657-013-0136-1

Lötters FJB, van den Bergh JP, de Vries F et al (2016) Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int 98:235–243. https://doi.org/10.1007/s00223-015-0089-zCrossRefPubMedPubMedCentral

Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. https://doi.org/10.1007/s00198-012-2074-yCrossRefPubMed

Klop C, Welsing PMJ, Elders PJM, Overbeek JA, Souverein PC, Burden AM, van Onzenoort H, Leufkens HG, Bijlsma JW, de Vries F (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int 26:1831–1840. https://doi.org/10.1007/s00198-015-3084-3CrossRefPubMedPubMedCentral

Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis-a large-scale, long-term retrospective study in the Netherlands. Osteoporos Int 22:1537–1546. https://doi.org/10.1007/s00198-010-1372-5CrossRefPubMed

Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9:e027049. https://doi.org/10.1136/bmjopen-2018-027049CrossRefPubMedPubMedCentral

Hiligsmann M, Rabenda V, Gathon HJ et al (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202–210. https://doi.org/10.1007/s00223-009-9329-4CrossRefPubMed

Ross S, Samuels E, Gairy K et al (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Heal 14:571–581. https://doi.org/10.1016/j.jval.2010.11.010CrossRef

Yeam CT, Chia S, Tan HCC, Kwan YH, Fong W, Seng JJB (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29:2623–2637. https://doi.org/10.1007/s00198-018-4759-3CrossRefPubMed

10.

Hiligsmann M, Salas M, Hughes DA et al (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907–2918. https://doi.org/10.1007/s00198-013-2364-zCrossRefPubMed

11.

Kini V, Ho PM (2018) Interventions to improve medication adherence: a review. JAMA 320:2461–2473. https://doi.org/10.1001/jama.2018.19271CrossRefPubMed

12.

Hiligsmann M, Cornelissen D, Vrijens B et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal. Osteoporos Int:1–11. https://doi.org/10.1007/s00198-019-05104-5

13.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:1–34. https://doi.org/10.1136/bmj.b2700CrossRef

14.

Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:1–6. https://doi.org/10.1371/journal.pmed.1000097CrossRef

15.

Lehane E, McCarthy G (2009) Medication non-adherence—exploring the conceptual mire. Int J Nurs Pract 15:25–31. https://doi.org/10.1111/j.1440-172X.2008.01722.xCrossRefPubMed

16.

Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.xCrossRefPubMedPubMedCentral

17.

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ Published Online First. https://doi.org/10.1136/bmj.l4898

18.

Sterne JA, Hernán MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ Published Online First. https://doi.org/10.1136/bmj.i4919

19.

von Elm E, Altman DG, Egger M et al (2014) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12:1495–1499. https://doi.org/10.1016/j.ijsu.2014.07.013CrossRef

20.

Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:698–702. https://doi.org/10.1136/bmj.c332CrossRef

21.

Ganda K, Schaffer A, Pearson S, Seibel MJ (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int 25:1345–1355. https://doi.org/10.1007/s00198-013-2610-4CrossRefPubMed

22.

Ducoulombier V, Luraschi H, Forzy G et al (2015) Contribution of phone follow-up to improved adherence to oral osteoporosis treatment. Am J Pharm Benefits 7:e81–e89 https://ajmc.s3.amazonaws.com/_media/_pdf/AJPB_0506_2015_Ducoulombier(final).pdf

23.

Tamechika S-Y, Sasaki K, Hayami Y et al (2018) Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. Arch Osteoporos 13:67. https://doi.org/10.1007/s11657-018-0451-7CrossRefPubMed

24.

Cram P, Wolinsky FD, Lou Y, Edmonds SW, Hall SF, Roblin DW, Wright NC, Jones MP, Saag KG, PAADRN Investigators (2016) Patient-activation and guideline-concordant pharmacological treatment after bone density testing: the PAADRN randomized controlled trial. Osteoporos Int 27:3513–3524. https://doi.org/10.1007/s00198-016-3681-9CrossRefPubMedPubMedCentral

25.

Danila MI, Outman RC, Rahn EJ, Mudano AS, Redden DT, Li P, Allison JJ, Anderson FA, Wyman A, Greenspan SL, LaCroix A, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Curtis JR, Warriner AH, Wright NC, Saag KG (2018) Evaluation of a multimodal, direct-to-patient educational intervention targeting barriers to osteoporosis care: a randomized clinical trial. J Bone Miner Res 33:763–772. https://doi.org/10.1002/jbmr.3425CrossRefPubMedPubMedCentral

26.

van den Berg P, van Haard PMM, van der Veer E et al (2018) A dedicated fracture liaison service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates. Osteoporos Int 29:813–824. https://doi.org/10.1007/s00198-017-4340-5CrossRefPubMed

27.

Bianchi ML, Duca P, Vai S, Guglielmi G, Viti R, Battista C, Scillitani A, Muscarella S, Luisetto G, Camozzi V, Nuti R, Caffarelli C, Gonnelli S, Albanese C, de Tullio V, Isaia G, D'Amelio P, Broggi F, Croci M (2015) Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int 26:1629–1638. https://doi.org/10.1007/s00198-015-3038-9CrossRefPubMed

28.

LeBlanc A, Wang AT, Wyatt K, Branda ME, Shah ND, van Houten H, Pencille L, Wermers R, Montori VM (2015) Encounter decision aid vs. clinical decision support or usual care to support patient-centered treatment decisions in osteoporosis: the osteoporosis choice randomized trial II. PLoS One 10:e0128063. https://doi.org/10.1371/journal.pone.0128063CrossRefPubMedPubMedCentral

29.

Roux S, Beaulieu M, Beaulieu MC, Cabana F, Boire G (2013) Priming primary care physicians to treat osteoporosis after a fragility fracture: an integrated multidisciplinary approach. J Rheumatol 40:703–711. https://doi.org/10.3899/jrheum.120908CrossRefPubMed

30.

Tüzün Ş, Akyüz G, Eskiyurt N, Memiş A, Kuran B, İçağasıoğlu A, Sarpel T, Özdemir F, Özgirgin N, Günaydın R, Cakçı A, Yurtkuran M (2013) Impact of the training on the compliance and persistence of weekly bisphosphonate treatment in postmenopausal osteoporosis: a randomized controlled study. Int J Med Sci 10:1880–1887. https://doi.org/10.7150/ijms.5359CrossRefPubMedPubMedCentral

31.

Gonnelli S, Caffarelli C, Rossi S, di Munno O, Malavolta N, Isaia G, Muratore M, D'Avola G, Gatto S, Minisola G, Nuti R (2016) How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study. Aging Clin Exp Res 28:459–468. https://doi.org/10.1007/s40520-016-0538-1CrossRefPubMed

32.

Oral A, Lorenc R (2015) Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: a multicenter, prospective, parallel group study. Acta Orthop Traumatol Turc 49:67–74PubMed

33.

Stuurman-Bieze AGG, Hiddink EG, Van Boven JFM (2014) Proactive pharmaceutical care interventions decrease patients’ nonadherence to osteoporosis medication. Osteoporos Int 25:1807–1812. https://doi.org/10.1007/s00198-014-2659-8CrossRefPubMed

34.

Seuffert P, Sagebien CA, McDonnell M (2016) Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice. Arch Osteoporos 11:1–6. https://doi.org/10.1007/s11657-016-0262-7CrossRef

35.

Beaton DE, Mamdani M, Zheng H, Jaglal S, Cadarette SM, Bogoch ER, Sale JEM, Sujic R, Jain R, Ontario Osteoporosis Strategy Fracture Clinic Screening Program Evaluation Team (2017) Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program: an interrupted time series analysis. Medicine (Baltimore) 96:e9012. https://doi.org/10.1097/MD.0000000000009012CrossRef

36.

Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48–54. https://doi.org/10.1016/j.bone.2013.10.006CrossRefPubMed

37.

Edmonds SW, Wolinsky FD, Christensen AJ et al (2013) The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health. Contemp Clin Trials 34:90–100. https://doi.org/10.1016/j.cct.2012.10.002CrossRefPubMed

38.

Schulz KF, Altman DG, Moher D, et al. (2013) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials of TO. Ann Intern Med 1996

39.

Jensen AL, Lomborg K, Wind G et al (2014) Effectiveness and characteristics of multifaceted osteoporosis group education-a systematic review. Osteoporos Int 25:1209–1224. https://doi.org/10.1007/s00198-013-2573-5CrossRefPubMed

40.

Solomon DH, Iversen MD, Avorn J et al (2012) Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 172:477–483. https://doi.org/10.1001/archinternmed.2011.1977CrossRefPubMedPubMedCentral

41.

Morfeld J-C, Vennedey V, Müller D, Pieper D, Stock S (2017) Patient education in osteoporosis prevention: a systematic review focusing on methodological quality of randomised controlled trials. Osteoporos Int 28:1779–1803. https://doi.org/10.1007/s00198-017-3946-yCrossRefPubMed

42.

Presley B, Groot W, Pavlova M (2018) Pharmacy-led interventions to improve medication adherence among adults with diabetes: a systematic review and meta-analysis. Res Soc Adm Pharm:1–11. https://doi.org/10.1016/j.sapharm.2018.09.021

43.

Seng EK, Rains JA, Nicholson RA, Lipton RB (2015) Improving medication adherence in migraine treatment. Curr Pain Headache Rep 19:1–7. https://doi.org/10.1007/s11916-015-0498-8CrossRef

44.

Bowers BL, Drew AM, Verry C (2018) Impact of pharmacist-physician collaboration on osteoporosis treatment rates. Ann Pharmacother 52:876–883. https://doi.org/10.1177/1060028018770622CrossRefPubMed

45.

Jameson JP, Baty PJ (2010) Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care

46.

Chow S (2017) Nurse practitioner fracture liaison role: a concept analysis. Orthop Nurs 36:385–391. https://doi.org/10.1097/NOR.0000000000000399CrossRefPubMed

47.

Toh LS, Lai PSM, Othman S, Wong KT, Low BY, Anderson C (2017) An analysis of inter-professional collaboration in osteoporosis screening at a primary care level using the D’Amour model. Res Soc Adm Pharm 13:1142–1150. https://doi.org/10.1016/j.sapharm.2016.10.004CrossRef

48.

Tan ECK, George J, Stewart K, Elliott RA (2014) Improving osteoporosis management in general practice: a pharmacist-led drug use evaluation program. Drugs Aging 31:703–709. https://doi.org/10.1007/s40266-014-0194-0CrossRefPubMed

Title: Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review
Authors: D. Cornelissen
S. de Kunder
L. Si
J.-Y. Reginster
S. Evers
A. Boonen
M. Hiligsmann
On behalf of the European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
Publication date: 01-09-2020
Publisher: Springer London
Keywords: Osteoporosis
Osteoporosis
Published in: Osteoporosis International / Issue 9/2020
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-020-05378-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2020

Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial

Effect of progestogen-only contraception on premenopausal fracture risk: a case-control study

Effect of fall characteristics on the severity of hip impact during a fall on the ground from standing height

Effects of anti-resorptive drugs on implant survival and peri-implantitis in patients with existing osseointegrated dental implants: a retrospective cohort study

Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography

Bone densitometry worldwide: a global survey by the ISCD and IOF